Aesthetic Medicine

U.S. FDA approves Captique, a new nonanimal stabilized hyaluronic acid

Published in Medical Letter on the CDC and FDA, January 16th, 2005

Inamed Corp. (IMDC) and Genzyme Corp. (GENZ) announced that the U.S. Food and Drug Administration (FDA) has granted market approval for Captique Injectable gel - a new dermal filler product based on Genzyme's nonanimal stabilized hyaluronic acid (HA) technology.

Captique is the newest hyaluronic acid entry into the U.S. dermal filler marketplace. It is indicated for the correction of moderate-to-severe facial wrinkles and is manufactured by Genzyme. Inamed is Genzyme's exclusive U.S. marketing and distribution partner for Captique.

"We are excited with the FDA's approval of Captique, our initial nonanimal stabilized hyaluronic acid-based dermal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry